Corbus Pharmaceuticals Holdings (CRBP) Total Current Liabilities (2013 - 2025)

Corbus Pharmaceuticals Holdings' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $20.7 million for Q4 2025.

• On a quarterly basis, Total Current Liabilities rose 75.09% year-over-year to $20.7 million in Q4 2025; TTM through Dec 2025 was $20.7 million, a 75.09% increase from a year earlier, with the FY2025 full-year figure at $20.7 million, up 75.09% from the prior year.
• Total Current Liabilities grew to $20.7 million in Q4 2025 per CRBP's latest filing, from $17.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $31.9 million in Q4 2023 and bottomed at $11.6 million in Q1 2025.
• The 5-year median for Total Current Liabilities is $17.0 million (2021), against an average of $18.4 million.
• Across the five-year window, Total Current Liabilities surged 152.33% in 2023 and sank 63.14% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $17.0 million in 2021, then decreased by 25.68% to $12.6 million in 2022, then surged by 152.33% to $31.9 million in 2023, then sank by 62.95% to $11.8 million in 2024, then jumped by 75.09% to $20.7 million in 2025.
• Per Business Quant, the three latest CRBP Total Current Liabilities figures stand at $20.7 million (Q4 2025), $17.1 million (Q3 2025), and $13.3 million (Q2 2025).